US Pharma MarketingSandoz unveils plan for biosimilar expansion and new $300M factory in Slovenia
Sandoz targets more than 100 biosimilars by 2040 under its Bio100 plan and will invest $300M in a new Ljubljana drug substance plant. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The…
LONDON — Sandoz is betting big on its newly formed biosimilar unit, as it reveals plans to grow its pipeline there by more than sevenfold and also invests $300 million in a new biosimilar manufacturing site.
...
Source: Endpoints News